Frazier was among the most active venture investors in 2024, according to analysts at William Blair, backing 17 private life ...

In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

The vaccine maker’s board intends to recommend a pending offer from investment firms Nordic Capital and Permira, which would ...

Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its ...

Hong Kong-based CSPC will receive $120 million from Madrigal under the deal. Elsewhere, Apellis and PTC Therapeutics won FDA ...

The abrupt exit of the former CBER director raises questions about the FDA’s leadership. For now, newly appointed CDER head ...

The new direct-to-consumer ad signals J&J’s confidence in its capacity to meet demand for the cell therapy after earlier ...

Prasad's exit ends a tumultuous tenure during which he led a reworking of agency guidelines on COVID vaccines and his office ...

Trial data showed the drug dramatically reduced cancer progression risk in certain patients, supporting Celcuity’s plans to ...

A deal with US WorldMeds includes the FDA-approved TCR therapy Tecelra and two clinical-stage cancer medicines.

The company plans to direct resources away from a drug developed by subsidiary Recognify Life Sciences and toward Atai’s ...